Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 22  •  04:00PM ET
1.75
Dollar change
0.00
Percentage change
0.00
%
Index
-
P/E
-
EPS (ttm)
-0.53
Insider Own
72.44%
Shs Outstand
141.98M
Perf Week
5.42%
Market Cap
528.43M
Forward P/E
-
EPS next Y
-0.66
Insider Trans
0.00%
Shs Float
39.13M
Perf Month
-12.50%
Enterprise Value
1.59B
PEG
-
EPS next Q
-0.14
Inst Own
34.89%
Perf Quarter
-18.98%
Income
-72.29M
P/S
593.74
EPS this Y
-23.95%
Inst Trans
0.42%
Perf Half Y
-24.57%
Sales
0.89M
P/B
-
EPS next Y
-2.89%
ROA
-20.69%
Perf YTD
-21.88%
Book/sh
-7.21
P/C
2.35
EPS next 5Y
10.52%
ROE
-
52W High
7.13 -75.46%
Perf Year
137.48%
Cash/sh
0.74
P/FCF
-
EPS past 3/5Y
33.55% 12.93%
ROIC
-
52W Low
0.54 224.07%
Perf 3Y
-82.52%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-549.38%
Volatility
8.48% 6.60%
Perf 5Y
-
Dividend TTM
-
EV/Sales
1791.19
EPS Y/Y TTM
12.60%
Oper. Margin
-18959.73%
ATR (14)
0.12
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
9.06
Sales Y/Y TTM
190.52%
Profit Margin
-8131.50%
RSI (14)
45.69
Dividend Gr. 3/5Y
- -
Current Ratio
9.06
EPS Q/Q
-8.87%
SMA20
-2.40%
Beta
1.72
Payout
-
Debt/Eq
-
Sales Q/Q
-1.74%
SMA50
-6.82%
Rel Volume
0.56
Prev Close
1.75
Employees
231
LT Debt/Eq
-
SMA200
-23.91%
Avg Volume
855.01K
Price
1.75
IPO
Jun 30, 2021
Option/Short
Yes / Yes
Trades
Volume
479,738
Change
0.00%
Date Action Analyst Rating Change Price Target Change
Dec-16-25Initiated H.C. Wainwright Buy $12
Jun-30-25Downgrade BofA Securities Neutral → Underperform $1
Sep-30-24Initiated JP Morgan Neutral
Sep-10-24Initiated Guggenheim Buy $6
Mar-07-24Resumed Morgan Stanley Equal-Weight $3
Jan-02-24Downgrade BofA Securities Buy → Neutral
Jul-25-23Initiated BTIG Research Buy $16
Dec-21-22Initiated Jefferies Buy $15
Nov-10-22Initiated Morgan Stanley Equal-Weight $13
Oct-18-22Initiated UBS Buy $18
May-15-26 11:45AM
Mar-25-26 04:01PM
Mar-18-26 04:00PM
Mar-04-26 05:15PM
Jan-06-26 07:30AM
07:43AM Loading…
Dec-27-25 07:43AM
Dec-16-25 11:53AM
Nov-10-25 04:15PM
Nov-06-25 11:00AM
Oct-29-25 07:30AM
Oct-20-25 07:30AM
Sep-20-25 02:43AM
Aug-27-25 07:30AM
Aug-12-25 04:01PM
Jul-22-25 11:03AM
04:52AM Loading…
04:52AM
Jul-20-25 12:35AM
Jul-17-25 12:00PM
10:00AM
06:40AM
05:38AM
Jul-16-25 12:00PM
Jul-15-25 07:30AM
Jul-14-25 09:45AM
Jul-12-25 07:30AM
Jul-09-25 12:26PM
07:51AM
07:30AM
Jul-08-25 05:09PM
07:00AM
12:43PM Loading…
Jul-01-25 12:43PM
Jun-30-25 09:36AM
May-12-25 04:15PM
Mar-21-25 09:55AM
Mar-17-25 07:30AM
Jan-07-25 07:30AM
Nov-26-24 07:30AM
Nov-12-24 07:30AM
Nov-05-24 07:30AM
Oct-22-24 07:02PM
Oct-14-24 07:30AM
Oct-09-24 07:30AM
Sep-04-24 01:33PM
Sep-03-24 07:30AM
Aug-27-24 07:30AM
Aug-09-24 07:00AM
Jun-27-24 05:52AM
Jun-26-24 02:10PM
Jun-17-24 07:00AM
Jun-11-24 09:35PM
07:40AM
Jun-10-24 04:15PM
07:32AM
06:30AM
May-29-24 07:00AM
May-21-24 07:00AM
May-10-24 03:43PM
01:54PM
07:48AM
07:00AM
Mar-25-24 06:05AM
Mar-21-24 07:49PM
Feb-29-24 04:05PM
Dec-29-23 08:22AM
Dec-13-23 09:55AM
Nov-30-23 06:05AM
Nov-24-23 06:40AM
Nov-21-23 06:05AM
Nov-17-23 01:38PM
Nov-16-23 09:35AM
Nov-14-23 07:04AM
06:05AM
Nov-13-23 05:02PM
Oct-30-23 04:12PM
Oct-17-23 09:35AM
Oct-16-23 02:50PM
Oct-12-23 03:05PM
Sep-06-23 12:14PM
Sep-05-23 06:05AM
Aug-31-23 10:33AM
Aug-29-23 01:16PM
Aug-11-23 02:21PM
Aug-10-23 04:10PM
Jul-18-23 06:05AM
Jul-17-23 06:05AM
Jun-13-23 12:05PM
Jun-01-23 04:05PM
May-11-23 04:01PM
May-04-23 06:05AM
Apr-25-23 02:00PM
Mar-28-23 04:12PM
Mar-03-23 06:05AM
Jan-11-23 07:48AM
Jan-10-23 04:05PM
Dec-27-22 11:05AM
08:46AM
Dec-22-22 06:05AM
Nov-16-22 11:22AM
Nov-14-22 06:05AM
Nov-11-22 04:05PM
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
CEO & DirectorDr. Bruce Culleton M.D.
Chief Financial OfficerMr. James Coulston CPA
J.D.Mr. Todd C. Girolamo Esq.
EVP of Science and TechnologyDr. Ulrich Ernst Ph.D.
Chief Information OfficerMr. Richard Williams
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pereira Brian JGDirectorNov 13 '25Sale2.37502,1361,190,0620Nov 14 04:07 PM
Pereira Brian JGDirectorNov 12 '25Sale2.72255,026694,51554,333Nov 14 04:07 PM
Brian PereiraDirectorNov 12 '25Proposed Sale2.70675,2341,823,131Nov 12 04:42 PM
Brian PereiraDirectorNov 12 '25Proposed Sale2.7081,928221,205Nov 12 04:30 PM
Weber Darin J.Chief Regulatory OfficerJul 08 '25Sale3.02103,480312,5100Jul 09 04:28 PM
DARIN J WEBEROfficerJul 08 '25Proposed Sale0.61103,48062,761Jul 08 04:20 PM